<DOC>
	<DOC>NCT01136694</DOC>
	<brief_summary>The purpose of this study is to explore the differences in productivity loss and costs between patients being treated for rheumatoid arthritis (RA) with biologic disease-modifying antirheumatic drugs (bDMARDs) compared to patients treated with conventional DMARDs.</brief_summary>
	<brief_title>Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)</brief_title>
	<detailed_description>Time Perspective: Prospective with some retrospective analysis of claims data</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Evidence of a bDMARD or DMARD during the identification period (01 February 2009 31 July 2009) 18 years of age or older at the index year At least 12 months of continuous enrollment in a large commercial US health plan affiliated with i3 Innovus, including the at least 6 months and up to 12 months prior the index date (i.e., the preindex period) and at least 6 months following the index date (i.e., the postindex (followup) period) Diagnosis of RA (reported on baseline survey) Diagnosis of psoriasis, plaque psoriasis, or psoriatic arthritis (ICD9 code 696.0x, or 696.1x), ankylosing spondylitis (720.0x), Crohn's disease (555.x), nonHodgkins lymphoma (200.xx, 202.0x202.2x, 202.7x202.8x), or ulcerative colitis (556.x) in any position at any time during the 18month identification period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>